eslicarbazepine acetate + metformin

**Eslicarbazepine acetate + metformin** is a combination of two therapeutic agents: eslicarbazepine acetate, an antiepileptic drug primarily indicated for partial-onset (focal) seizures, and metformin, an oral antidiabetic agent used to treat type 2 diabetes mellitus. Eslicarbazepine acetate acts by enhancing the slow inactivation of voltage-gated sodium channels and inhibiting T-type calcium channels, thereby reducing abnormal neuronal firing and seizure activity. Metformin decreases hepatic glucose production, improves insulin sensitivity, and increases peripheral glucose uptake. This combination may be used in patients with epilepsy and comorbid diabetes or investigated for potential treatment of neuropathic pain of diabetic origin[1][2][5]. Clinical evidence indicates that eslicarbazepine acetate does not significantly alter the pharmacokinetics of metformin[1][5].

Other names

eslicarbazepine acetate + metformin